Other Events ·
Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of preclinical data for Telomir-Zn in…
TELOTelomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of preclinical data for Telomir-Zn in Biomedicine & Pharmacotherapy, demonstrating dose-dependent improvements in glucose homeostasis and insulin resistance in a zebrafish model of Type 2 diabetes. The findings support the mechanism of action for Telomir-Zn, which has received FDA IND clearance for a Phase 1/2 clinical trial in triple-negative breast cancer. Telomir Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing clinical-stage lead programs.